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Abstract

Boronic acids have been successfully employed as inhibitors of hydrolytic enzymes. Typically, an enzymatic
nucleophile catalyzing hydrolysis adds to the electrophilic boron atom forming a tetrahedral species that mimics
the intermediate(s)/transition state(s) for the hydrolysis reaction. We show that para-substituted phenylboronic
acids (PBAs) are potent competitive inhibitors of mandelate racemase (MR), an enzyme that catalyzes a 1,1proton transfer rather than a hydrolysis reaction. The Ki value for PBA was 1.8 ± 0.1 μM, and p-Cl-PBA exhibited
the most potent inhibition (Ki = 81 ± 4 nM), exceeding the binding affinity of the substrate by ∼4 orders of
magnitude. Isothermal titration calorimetric studies with the wild-type, K166M, and H297N MR variants
indicated that, of the two Brønsted acid–base catalysts Lys 166 and His 297, the former made the greater
contribution to inhibitor binding. The X-ray crystal structure of the MR·PBA complex revealed the presence of
multiple H-bonds between the boronic acid hydroxyl groups and the side chains of active site residues, as well as
formation of a His 297 Nε2–B dative bond. The dramatic upfield change in chemical shift of 27.2 ppm in the
solution-phase 11B nuclear magnetic resonance spectrum accompanying binding of PBA by MR was consistent
with an sp3-hybridized boron, which was also supported by density-functional theory calculations. These
unprecedented findings suggest that, beyond substituting boron at carbon centers participating in hydrolysis
reactions, substitution of boron at the acidic carbon center of a substrate furnishes a new approach for
generating inhibitors of enzymes catalyzing the deprotonation of carbon acid substrates.

Over the past decade, interest in employing boron in the design of enzyme inhibitors and potential therapeutic
agents has grown.(1−9) This interest arises because boron-containing biomolecules exhibit low toxicity(6) and
are not abundant in nature, although natural boron-containing antibiotics and cell surface signaling molecules
do exist.(10) Moreover, the boron atom acts as a Lewis acid(11) with its vacant p orbital readily accepting
electrons from donor atoms to form a coordinate covalent (dative) bond with concomitant conversion from a
neutral sp2 center to an anionic sp3 center. The electron donors are typically the side chains of
Ser,(12−15) Thr,(16) His,(17,18) or Lys,(19) which can interact directly with the boron atom or via an intervening
water molecule(20) (Scheme 1). Furthermore, the boron atom is often covalently linked to one or two hydroxyl
groups; hence, it can act as an acceptor or donor of H-bonds for additional molecular
recognition.(21) Consequently, enzymes often bind boron-based inhibitors with high affinity such that the
inhibition is effectively irreversible.(6) Traditionally, the boronic acid group has been employed for the design of
inhibitors of hydrolytic enzymes, where either water(22) or the hydroxyl group of a Ser or Thr residue of the
enzyme(5,6,9,23) reacts with the trigonal planar boronic acid group to yield a tetrahedral adduct that mimics the
geometric and electronic features of the tetrahedral intermediate(s) and/or transition states (TSs) formed
during hydrolysis (Scheme 1). We hypothesized that the Lewis acidity of the boronic acid functional group might
also permit strong interactions with the Brønsted base catalyst(s) present at the active sites of enzymes that

catalyze heterolytic cleavage of a C–H bond. Indeed, many different enzymes catalyze such proton abstraction
reactions, often to initiate 1,1-, 1,2-, or 1,3-migrations of protons, aldol or Claisen condensations, or βelimination reactions.(24−26) Racemases and epimerases that utilize a two-base mechanism(27) offer
particularly attractive targets because the Brønsted acid–base catalysts are located on opposite sides of the
carbon atom where deprotonation occurs. This active site architecture should afford the potential for
interactions between the enzyme and the boron atom of an inhibitor.

Scheme 1. Typical Adducts Formed between the Side Chains of Protein Amino Acid Residues and Boronic Acid
Ligands
As a model system, we explored the inhibition of mandelate racemase (MR) by various boronic acids. MR has
served as a powerful paradigm for developing our understanding of how enzymes overcome the thermodynamic
and kinetic barriers accompanying the abstraction of a proton from a carbon acid substrate, as well as our
general understanding of enzyme catalysis.(24,28−31) The enzyme utilizes a two-base mechanism with either
Lys 166 or His 297 acting as the enantiospecific Brønsted base to abstract the α-proton from (S)- or (R)mandelate, respectively (Scheme 2).(32−34) The resulting aci-carboxylate intermediate is subsequently
reprotonated by the conjugate acid of the Brønsted base, located antipodal to the Brønsted base that effected
deprotonation, to afford the enantiomeric product. Considering the arrangement of the Lys and His side chains
around the stereogenic α-carbon, we envisioned that potent inhibition might arise if a bound boron-bearing
inhibitor positioned the boron atom at the location normally occupied by the α-carbon of the substrate, thereby
allowing for formation of N–B interactions.(35−42) Herein, we report that derivatives of phenylboronic acid
(PBA) are the most potent inhibitors of MR yet described, exceeding the binding affinity of TS analogue
inhibitors by ∼1–2 orders of magnitude.(43,44) X-ray crystallographic studies reveal that the boronic acid moiety
of the inhibitor is “gripped” by key catalytic residues at the active site, capitalizing on the ability of the boronic
acid group to form multiple H-bonds. Moreover, crystallographic and 11B nuclear magnetic resonance (NMR)
evidence supports the formation of an N–B dative bond between PBA and the Brønsted acid–base catalyst His
297. Our results suggest that replacement of the acidic carbon of a carbon acid substrate with an electrophilic
boron atom expands the scope of boronic acids beyond their use as carboxylate isosteres and as inhibitors
targeting hydrolytic enzymes.

Scheme 2. Reaction Catalyzed by Mandelate Racemase

Materials and Methods
General

All reagents, unless mentioned otherwise, were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON). 4Methylphenylboronic acid and methylboronic acid were purchased from TCI America (Portland, OR). The (R)and (S)-enantiomers of 4-chloromandelic acid were purchased from DSM Pharma Chemicals Regensburg GmbH
(Regensburg, Germany). Circular dichroism (CD) spectral measurements were conducted using a JASCO J-810
spectropolarimeter (Jasco Inc., Easton, MI). Binding studies were conducted using a VP-ITC microcalorimeter
(MicroCal, Inc., Northampton, MA). 11B NMR spectra were recorded using a Brüker AVANCE 500 NMR
spectrometer at the Dalhousie Nuclear Magnetic Resonance Research Resource (NMR-3) Centre.

Enzyme Purification

StrepII-tagged recombinant variants of MR (wild-type MR, K166M-MR, and H297N-MR)(45) were overexpressed
in and purified from Escherichia coli BL21(DE3) cells transformed with the appropriate plasmid as described
previously.(46) These constructs encode the wild-type or mutant MR gene products as fusion proteins with an
N-terminal StrepII tag (MASWSHPQFEKGALEVLFQGPGYHM1-MR, where M1 denotes the initial Met of either the
wild-type or variant MRs and the StrepII tag is underlined). The purity of the wild-type and variant MRs (≥99%)
was assessed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (12% acrylamide) with staining
by Coomassie blue R-250.(47) Protein concentrations were determined from the intrinsic enzyme absorbance at
280 nm using an extinction coefficient ε of 53400 M–1 cm–1 for all MR variants estimated using the ProtParam
program from ExPasy (http://web.expasy.org/protparam/).(48) The StrepII tag was not removed from the
enzymes.

Inhibition Studies

MR activity was assayed using a CD-based assay by following the change in ellipticity of mandelate at 262 nm
with a 1 cm light path (unless otherwise indicated) as described by Sharp et al.(49) All inhibition experiments
were conducted at 25 °C in Na+-HEPES buffer (0.1 M, pH 7.5) containing MgCl2 (3.3 mM) and bovine serum
albumin (BSA, 0.005%). Wild-type MR (150 ng/mL) was assayed with (R)-mandelate (0.5–15.0 mM) as the
substrate and varying concentrations of PBA (1.00, 2.00, and 5.00 μM), 4-Br-PBA (0.08, 0.16, and 0.24 μM), 4-ClPBA (0.08, 0.16, and 0.24 μM), 4-CH3-PBA (0.50, 1.00, and 1.50 μM), 4-CF3-PBA (0.25, 0.50, and 0.75 μM), 4-CNPBA (2.50, 5.00, and 7.50 μM), 4-F-PBA (0.20, 0.40, and 0.60 μM), 4-NO2-PBA (0.50, 1.00, and 1.50 μM), 4-OCH3PBA (4.00, 8.00, and 12.00 μM), cyclohexylboronic acid (1.50, 3.00, and 4.20 mM), and methylboronic acid
(0.125, 0.250, and 0.375 M). The apparent kinetic constants Vmax and Km were determined by fitting eq 1 to the
initial velocity data using nonlinear regression analysis and KaleidaGraph ver. 4.02 from Synergy Software
(Reading, PA). All kinetic parameters were determined in triplicate, and average values are reported. The
reported errors are the standard deviations.

𝑣𝑣𝑖𝑖 =

(1)

𝑉𝑉max [𝑆𝑆]
𝐾𝐾m + [𝑆𝑆]

Competitive inhibition constants (Ki) for the inhibition of MR by the 4-substituted PBAs were determined from
plots of the apparent Km/Vmax values versus inhibitor concentration in accord with eq 2.(50)

𝑣𝑣𝑖𝑖 =
(2)

𝑉𝑉max [𝑆𝑆]
[𝐼𝐼]
𝐾𝐾m �1 + � + [𝑆𝑆]
𝐾𝐾i

The IC50 values for the inhibition of wild-type MR by 4-Cl-PBA (40–640 nM) at MR concentrations of 150, 300,
and 450 ng/mL were determined, relative to (R)-mandelate (1.0 mM), by fitting eq 3 to the relative velocities
(vi/v0) obtained at the indicated concentrations. The IC50 value is the concentration of the inhibitor that yields
a vi/v0 of 0.5, and n is the Hill number.(50)

(3)

IC𝑁𝑁
𝑣𝑣𝑖𝑖
50
= 𝑁𝑁
𝑣𝑣0 IC50 + [I]𝑁𝑁

Reversibility and Effect of Enzyme Concentration

The reversibility of inhibition by PBA were evaluated by measuring the recovery of enzyme activity after dialysis.
Wild-type MR (1500 ng/mL) was incubated with PBA (0 μM, as a control, and 30 μM each in 3.0 mL) at 25 °C for
20 min, yielding 10% of the enzymatic activity. After dialysis against assay buffer (3 × 250 mL over 24 h), both the
control and PBA-containing samples were assayed for enzymatic activity.

Assay with 4-Chloromandelate

The ability of MR to catalyze the racemization of (R)- and (S)-4-chloromandelate was examined using a CD-based
assay. The CD spectra of (R)- and (S)-4-chloromandelate (10 mM) in assay buffer were recorded, and a suitable
wavelength at which 4-chloromandelate exhibited a pronounced signal was chosen (276 nm). The molar
ellipticity was estimated to be 5189 ± 12 deg cm2 mol–1 from the slope of a plot of the observed ellipticity at 276
nm against five concentrations of (R)-4-chloromandelate (2.0, 4.0, 6.0, 8.0, and 10.0 mM). The values
of kcat (Vmax/[E]T) and Km were then determined in accord with eq 1 by measuring the initial rates for the
racemization of (R)- and (S)-4-chloromandelate (0–10 mM) catalyzed by wild-type MR (150 ng/mL).

Isothermal Titration Calorimetry

Ligand solutions containing PBA were prepared in the final dialysis buffer to eliminate heat signals that could
arise from buffer mismatch. MR variants and ligand solutions were degassed (Microcal Thermovac) for 15 min
prior to being loaded into the sample cell (1.46 mL) and the injection syringe (297 μL), respectively. The stirred
cell contained either wild-type MR (45 μM), H297N-MR (50 μM), or K166M-MR (60 μM), and the injection
syringe contained various concentrations of PBA (1.0 mM, 6.0 μL/injection with wild-type MR; 2.0 mM, 6.0
μL/injection with H297N-MR; and 26.22 mM, 6.0 μL/injection with K166M-MR). Titrations were conducted at 20
°C. The heat released due to the initial injection (typically 2–5 μL) was excluded from data analyses to minimize
the effect of diffusion of the titrant from the syringe tip during the equilibration process. To correct for the heats
of dilution and mixing, ligand titrations were also conducted with the sample cell containing only buffer. The

dilution isotherm for each ligand was subtracted from the appropriate binding isotherm prior to curve fitting.
Binding affinities and the ΔH and ΔS values for binding of PBA to the MR variants were obtained by fitting the
calorimetric data with a single-site model using the Origin 7.0 software (OriginLab, Northampton, MA). For
K166M-MR, the binding of PBA was weak and the experiment was limited by our inability to utilize higher
concentrations of PBA due to precipitation of the protein. Curve fitting was therefore conducted by fixing the
molar ratio (n) at 1.

B NMR Spectroscopy

11

All NMR spectra were recorded at 25 °C in Na+-HEPES buffer (0.1 M, pH 7.5) containing MgCl2 (3.3 mM) and D2O
(10%). Chemical shifts (δ) of the signals arising from 11B are reported relative to an external standard of
BF3·OEt2 (δ = 0.00 ppm). Samples were in 5 mm quartz tubes (Sigma-Aldrich Canada Ltd.) to reduce the
background signal arising from the boron in borosilicate glass. For the spectra of PBA in the presence of MR, the
concentration of PBA was fixed at either 300 or 400 μM, and the spectra were recorded with varying amounts of
wild-type MR added to the solution (0–300 μM). The background signal arising from borosilicate glass in the
spectrometer probe was reduced in the spectra using Whittaker smoothing.(51)

Protein Crystallization

Crystals of wild-type MR were grown in the presence of PBA by the sitting-drop vapor diffusion method against a
reservoir volume of 500 μL. The protein solution and reservoir solution were mixed in a 1:1 ratio to give a final
volume of 10 μL. Crystals grew spontaneously at 21 °C. The reservoir solution consisted of PEG 4000 [10% (w/v)]
and Bis-Tris Propane (BTP; 50 mM, pH 7.0). The protein solution consisted of MR (6 mg/mL) purified as
described above, PBA (1.0 mM), MgCl2 (3.3 mM), and Na+-HEPES buffer (50 mM, pH 7.5). The resulting cubelike
crystals (∼50 μm × 40 μm × 40 μm) grew to full size within 15–20 days. Crystals were harvested and transferred
to a synthetic stabilizing solution consisting of PEG 4000 [8% (w/v)], BTP (80 mM, pH 7.0), ethylene glycol [5%
(w/v)], PBA (0.77 mM), MgCl2 (1.65 mM), and Na+-HEPES buffer (25 mM, pH 7.5). These stabilized crystals were
equilibrated in the synthetic stabilizing solution for 5 min and then transferred directly to a cryoprotectant
solution consisting of PEG 4000 [10% (w/v)], BTP (80 mM), ethylene glycol [20% (w/v)], PBA (0.8 mM),
MgCl2 (1.58 mM), and Na+-HEPES buffer (24 mM, pH 7.5). The cryoprotected crystals were flash-frozen in a
stream of nitrogen gas at 100 K.

Data Collection, Structure Determination, and Refinement

X-ray diffraction data were collected at the Life Sciences Collaborative Access Team beamline 21-ID-G at the
Advanced Photon Source, Argonne National Laboratory, on a Rayonix MarMosaic 300 CCD detector with an Xray wavelength of 0.979 Å. Diffraction images were autoprocessed using the autoPROC software
workflow,(52) which merged and scaled the isotropic data in AIMLESS(53) with the programs TRUNCATE(54) and
UNIQUE(55) to automatically determine the resolution limit. The phases were determined by the molecular
replacement method, using the wild-type MR enzyme with bound BzH [Protein Data Bank (PDB) entry 3UXK] as
the search model,(56) with the program Phaser.(57) The molecular replacement models were extended by
several rounds of manual model building with COOT(58) and refinement with Phenix.Refine(59) with an Xray/stereochemistry weight of 2.0 applied in the final rounds of refinement. Noncrystallographic restraints
between each monomer were applied for the first round of refinement but were relieved for subsequent
rounds. Water molecules were added to the model in COOT and Phenix.Refine with subsequent manual
verification. The final refined ligand coordinates for PBA were optimized for structure refinement using eLBOW
(electronic ligand building and optimization workbench).(60) For each dimer, one active site (chains A, C, E, and
G) was modeled with single occupancy by PBA with a C–B–Oα–Oβ dihedral angle of ∼145° (intermediate
between sp2- and sp3-hydridized), while the other active site in the adjacent subunit (chains B, D, F, and H) was
modeled at 50% occupancy by PBA with a C–B–Oα–Oβ dihedral angle of ∼165° (∼sp2-hydridized) and at 50%

occupancy by PBA with a C–B–Oα–Oβ dihedral angle of ∼120° (∼sp3-hydridized). The side chain of His 297 was
also modeled in two conformations for chains B, D, F, and H. The model was refined using a ligand definition file
for PBA with a C–B–Oα–Oβ dihedral angle of 145°, with loose restraints. For chains B, D, and F, the refinement
supported two distinct conformations for PBA and His 297, each at 50% occupancy. However, for chain H, the
refinement resulted in both conformations converging to a single conformation for His 297 and a single
conformation for PBA, with a C–B–Oα–Oβ dihedral angle of 166°. Consequently, subsequent refinements
modeled only a single conformation for PBA and His 297 in chain H. Data collection and processing statistics are
summarized in Table S1.

Density-Functional Theory (DFT) Calculations

All calculations were performed using the Gaussian 09(61) and postg(62) programs, with the LC-ωPBE density
functional.(63) The exchange-hole dipole moment (XDM) method(62,64) was used to include dispersion
interactions in all geometry optimizations, with the following damping-function parameters: a1 = 0.6889 and a2 =
1.9452 Å. The geometry optimizations used a mixed basis set, with the 6-31G* basis assigned to boron, carbon,
and hydrogen, and the larger 6-31+G* basis assigned to nitrogen and oxygen. The initial geometry was obtained
from the coordinates of chain F from the X-ray crystal structure of MR with bound PBA (PDB entry 6VIM) refined
with a single PBA at 100% occupancy (i.e., C–B–Oα–Oβ dihedral angle of 167.9°; His 297 Nε2–B and Lys 166 Nζ–B
distances of 2.50 and 2.99 Å, respectively) and a single conformation of His 297, utilizing the first shell of
residues interacting with PBA (Asn 197, Lys 164, Lys 166, and His 297), the Mg2+ ion and its ligands (H2O, Asp
195, Glu 221, and Glu 247), and Asp 270, which forms a catalytic dyad with His 297.(65) The amino acids were
truncated (by hydrogen capping) at the sp3 or α-carbon atoms, the positions of which were held fixed during
geometry optimizations, while all other atomic positions were allowed to relax. Several combinations of H atom
positions and protonation states were considered, and the most stable retained. The 11B NMR chemical shifts
were calculated with the Gauge-Independent Atomic Orbital (GIAO) method,(66) using the 6-31+G* basis set for
all atoms. Analogous calculations were also carried out for an isolated PBA molecule. The boron chemical shifts
are expressed relative to that for free PBA in assay buffer (i.e., δ = 28.2 ppm).

Results and Discussion
Inhibition of MR by PBAs

In accord with our hypothesis, PBA was a potent competitive inhibitor of MR with a Ki value of 1.8 μM (Table 1),
binding with an affinity ∼556-fold greater than that observed for the substrate (Km = KS ≈ 1 mM).(67) The onset
of inhibition was rapid, and dialysis of the enzyme–inhibitor solution resulted in full recovery of enzyme activity,
indicating that the inhibition was reversible. To investigate the dependence of the binding affinity on the
identity of substituents on the phenyl ring, we determined the Ki values for a series of 4-substituted PBAs
(Table 1 and Figures S1–S9). Plotting the observed log(KiX/KiH) values against the Hammett substituent constants
(σpara) gave a concave-up pattern (Figure 1).(68) The decreased binding affinity of PBA derivatives with bulky
electron-withdrawing substituents at the para position of the phenyl ring likely arose from unfavorable steric
and polar interactions as observed previously for the weak binding of 4-nitromandelate,(67) rather than
electronic effects. However, for the free energies accompanying binding of PBA derivatives bearing
smaller para substituents (H, CH3, F, Br, Cl, and, surprisingly, OCH3), there was a roughly linear correlation (ρ =
−2.9 ± 0.8) indicating that electron-withdrawing character favored binding. A similar observation was reported
for the inhibition of subtilisin by a limited number of phenylboronic acids (i.e., ρ = −0.895).(69) [Note that, as
shown in Figure S10, using the pKa values (Table S2) to adjust the Ki values assuming either the neutral trigonal
or anionic tetrahedral boronic acid was the inhibitor did not significantly alter the shape of the plot, nor did
plotting the data as a function of σ–para.] The most potent inhibitor was 4-Cl-PBA, binding with a Ki value
approximately 1.23 × 104-fold lower than that of the substrate.

Table 1. Inhibition of MR by Boronic Acids
compound
Ki (μM)a
PBA
1.8 ± 0.1
4-Br-PBA
0.123 ± 0.007
4-Cl-PBA
0.081 ± 0.004
IC50 = 0.149 ± 0.006 μM ([MR] = 150 ng/mL); IC50 =
0.14 ± 0.01 μM ([MR] = 300 ng/mL); IC50 = 0.142 ± 0.003 μM
([MR] = 450 ng/mL)
4-CH3-PBA
0.67 ± 0.07
4-CF3-PBA
0.21 ± 0.01
4-CN-PBA
2.93 ± 0.02
4-F-PBA
0.23 ± 0.01
4-NO2-PBA
0.66 ± 0.05
4-OCH3-PBA
4.1 ± 0.2
cyclohexylboronic acid (1.56 ± 0.05) × 103
methylboronic acid
Ki = (1.3 ± 0.1) × 105; αKi = (7.1 ± 0.1) × 105
a
Km = KS ≈ 1000 μM.(67)
b
Competitive (C) and linear mixed-type (LM) inhibition.

inhibition modeb
C
C
C

C
C
C
C
C
C
C
LM

Figure 1. Hammett plot for the inhibition of MR by para-substituted phenylboronic acids. The log(KiX/KiH) values,
where KiX is the observed Ki value for a given para-substituted PBA, are plotted against the para-substituent
constant (σpara). The line shown is the linear regression line [slope (ρ) = −2.9 ± 0.8] for the PBA derivatives for
which X = H, Br, Cl, CH3, F, and OCH3 (○). The bulkier electron-withdrawing groups (i.e., X = NO2, CN, and CF3)
likely deviate from the correlation due to unfavorable steric and polar effects on binding (●).(67)
To assess whether this enhanced binding arose from electronic effects or some fortuitous interaction(s) with the
chloro substituent, we determined the molar ellipticity of (R)- and (S)-4-chloromandelate (Figure S11) and
investigated the kinetic parameters for MR acting on 4-chloromandelate as an alternative substrate (Figure
S12).(70) Although the turnover numbers (kcat) for (R)-4-chloromandelate (1343 ± 43 s–1) and (S)-4chloromandelate (1329 ± 33 s–1) were greater than the corresponding values for (R)-mandelate (1029 s–1) and

(S)-mandelate (775 s–1),(71) the Km values of (R)-4-chloromandelate (1.09 ± 0.06 mM) and (S)-4-chloromandelate
(0.90 ± 0.07 mM) were similar to those of (R)-mandelate (1.03 ± 0.05 mM) and (S)-mandelate (0.76 ± 0.03 mM),
respectively.(71) Hence, the enhanced binding of 4-Cl-PBA likely arose from the electron-withdrawing effect of
the chloro substituent. Because 4-Cl-PBA exhibited the highest binding affinity of the PBA derivatives examined,
we determined the IC50 values for inhibition by 4-Cl-PBA at three different enzyme concentrations (Figure S13)
and found that they were independent of enzyme concentration (Table 1). This observation indicated that the
PBA derivatives were not behaving as tight-binding inhibitors and fell into “zone A” as defined by Straus and
Goldstein (i.e., Kiapp/[E]T > 10, and IC50 ∼ Kiapp).(72)
To explore the role of the phenyl ring in binding, we examined the ability of MR to bind cyclohexylboronic acid
and methylboronic acid (Table 1 and Figure 2). Cyclohexylboronic acid retains the hydrophobic nature of the
ligand but removes the planar and aromatic character. The 867-fold loss of binding affinity for cyclohexylboronic
acid (Figure S14) relative to PBA suggested that the aromaticity of the phenyl ring contributed ∼4.0 kcal/mol to
the overall change in free energy accompanying PBA binding. Strikingly, the additional loss of van der Waals
interactions resulting from replacement of the phenyl ring with a methyl group led to a massive 72000-fold loss
of binding affinity relative to PBA (Table 1). Interestingly, methylboronic acid exhibited linear mixed-type
inhibition kinetics (Figure S15), likely arising from concomitant weak binding of the compound at an allosteric
site (αKi = 710 mM).

Figure 2. Comparison of the free energy changes accompanying binding (ΔGbinding) of boronic acids and
hydroxamates. The ΔGbinding (=RT ln Ki) values of PBA (red), cyclohexylboronic acid (blue), and methylboronic acid
(purple) were calculated from the Ki values listed in Table 1. The ΔGbinding values for cyclohexylhydroxamate
(green) and BzH (orange) were calculated from their Ki values of 0.25 mM and 11.7 μM, respectively.(73)
MR binds PBA with an affinity that is ∼7-fold greater than that exhibited for the TS analogue inhibitor
benzohydroxamate (BzH; Ki = 11.7 μM).(73) Unlike PBA, replacement of the phenyl ring of BzH with a cyclohexyl
ring (i.e., cyclohexylhydroxamate; Ki = 0.25 mM)(73) revealed that aromaticity of the phenyl ring contributed
only ∼1.8 kcal/mol to the overall free energy change accompanying BzH binding (Figure 2). Thus, the aromatic
character of the inhibitor makes a more substantial contribution to the binding of PBA than to the binding of
BzH.
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To obtain information about the hybridization state of the boron of PBA when bound at the active site of MR in
the solution state, we utilized 11B NMR spectroscopy. This approach has been employed to study the interaction

of boronic acid-bearing inhibitors with β-lactamase,(74) γ-glutamyl transpeptidase,(75) and a variety of
proteases.(18,76−83) In the absence of MR, the boron of PBA exhibited a signal with a chemical shift of 28.2
ppm in the assay buffer (Figure 3A), which is in accord with previous studies(20,84) and arises from the neutral
trigonal boronic acid species [Ph−B(OH)2]. Upon addition of MR, a new peak was observed at 0.97 ppm
(Figure 3B–D), which was also the sole peak present when the enzyme and PBA were at equal concentrations
(Figure 3E), and suggested that there was slow exchange between the MR-bound PBA and free PBA.(79) The 11B
NMR signal from PBA bound to MR was significantly sharper than that of the free inhibitor, which has also been
observed for aryl boronic acid inhibitors bound to chymotrypsin.(18,78) The marked upfield shift of the 11B signal
of PBA in the presence of MR is consistent with additional electron density on the boron. Interestingly, the
upfield chemical shift to 0.97 ppm is greater than the chemical shift values of 2.6 and 5.7 ppm observed for PhB(OH)3– and for the imidazole complex with PBA, respectively.(20) Thus, the 11B NMR spectroscopic studies
suggested that the boron of bound PBA likely participated in an N–B interaction (vide infra) with Lys 166 and/or
His 297 and may exist either partially or fully in its anionic, sp3-hybridized state.

Figure 3. 11B NMR spectra of free PBA and PBA bound to wild-type MR. Shown are the observed 11B NMR spectra
(32000 scans per spectrum) of PBA (400 μM) (A) in the absence of enzyme or in the presence of (B) PBA (400
μM) and MR (90 μM), (C) PBA (400 μM) and MR (130 μM), (D) PBA (400 μM) and MR (180 μM), or (E) PBA (300
μM) and MR (300 μM). The disappearance of the signal at 28.2 ppm and the appearance of a new signal at 0.97
ppm are evident upon titration of PBA with MR. Note that the concentration of PBA was decreased to 300 μM in
panel E because concentrations of 400 μM for both MR and PBA led to precipitation of the protein. All solutions
contained Na+-HEPES buffer (0.1 M, pH 7.5), MgCl2 (3.3 mM), and D2O (10%). A low signal-to-noise ratio was
observed in the spectra because of the requirement to use amounts of inhibitor that were approximately
stoichiometric to the enzyme concentration, and higher concentrations of the enzyme (>300 μM) led to protein
precipitation at the concentrations of PBA employed. The weak signal at 18.9 ppm (*) in spectrum A likely
corresponds to a minor amount of boric acid and not the ∼5% of PBA that exists in the anionic form at pH 7.5
[pKaB = 8.8 (Table S2)].(85,86) The indicated 11B chemical shift values (parts per million) are relative to an
external standard of BF3·OEt2.

Contribution of the Brønsted Acid–Base Catalysts to Binding of PBA

Because the 11B NMR spectroscopic studies suggested the possibility of an N–B interaction, we examined the
effect of removing the side chains of Lys 166 (K166M) and His 297 (H297N) on the binding of PBA. Neither
K166M-MR nor H297N-MR is catalytically active;(32,45) however, the binding affinity of these variants for PBA

could be assessed using ITC. Although the binding event was only weakly exothermic, the thermograms for the
titration of wild-type-MR, K166M-MR, and H297N-MR with PBA (Figure 4) permitted clear differentiation among
the abilities of the three MR variants to bind PBA. As shown in Table 2, the Kd value (1.7 μM) for the binding of
PBA to wild-type MR was in excellent agreement with the Ki value (1.8 μM) determined from the inhibition
experiments. Most interestingly, K166M-MR bound PBA approximately 3 × 103-fold less tightly than wild-type
MR (ΔΔGbinding = 4.6 kcal/mol), while H297N-MR bound PBA only ∼30-fold less tightly than the wild-type enzyme
(ΔΔGbinding = 2.0 kcal/mol). A similar trend was reported for the binding of BzH with the wild-type, K166M
(ΔΔGbinding = 3.5 kcal/mol), and H297N (ΔΔGbinding = 1.2 kcal/mol) MR variants.(45) Thus, of the two Brønsted
acid–base catalysts, Lys 166 plays a dominant role in the recognition of PBA.
Table 2. Analysis of Binding Interactions with MR Variants at 20 °C Using ITC
MR variant Kd (μM)
ΔH (kcal/mol) ΔS (cal mol–1 K–1) ΔG (kcal/mol)
wild-type
1.7 ± 0.3
–0.96 ± 0.07
23.1 ± 0.5
–7.7 ± 0.1
K166Ma
4700 ± 400 –5.1 ± 0.5
–6.7 ± 1.8
–3.13 ± 0.05
H297N
52 ± 7
–1.08 ± 0.04
15.9 ± 0.4
–5.74 ± 0.08
a
Values estimated by fixing the molar ratio (n) at 1.

Figure 4. Representative thermograms (top) and binding isotherms (bottom) for MR variants binding PBA at 20
°C. Titrations of (A) wild-type MR (45 μM) with PBA (1 mM, 6 μL per injection), (B) K166M-MR (60 μM) with PBA
(26.22 mM, 6 μL per injection), and (C) H297N-MR (50 μM) with PBA (2 mM, 6 μL per injection). The first
injection in each case (top) was 3 μL and was omitted when calculating the thermodynamic parameters
(see Table 2). The molar ratio is [PBA]/[MR variant].

Structure of the MR·PBA Complex

To explore the possibility of formation of an N–B interaction with the side chains of Lys 166 and/or His 297, we
determined the X-ray crystal structure of the MR·PBA complex at 2.00-Å resolution. The complex crystallized as
a homooctamer in space group C121 due to subtle variations in the structures of the eight subunits and active
sites (Table S1). The individual subunits were very similar, with root-mean-square deviations (rmsds) for
structural alignments between the α-carbon atoms of the individual subunits ranging from 0.077 to 0.104 Å. In a
comparison of individual structural overlays with subunit A, subunits C, E, and G, representing the same face of
the octamer as subunit A, had smaller rmsds (0.082 ± 0.006 Å), while subunits B, D, F, and H, representing the
opposite face of the octamer from subunit A, had statistically larger rmsds (0.102 ± 0.001 Å). The electron
density for the PBA ligands was well-defined over the entire molecule, and all eight active sites of the octamer
were occupied by the ligand. PBA interacted with the Mg2+ ion and formed multiple H-bonds with the side chains
of active site residues (Figure 5A,B and Figure S16). The rmsds for structural alignments of the subunit A αcarbon atoms of the MR·PBA complex and apo-MR (PDB entry 2MNR)(87) and MR complexes with (S)atrolactate (PDB entry 1MDR),(33) BzH (PDB entry 3UXK),(56) and Cupferron (Cfn, PDB entry 3UXL)(56) were
0.254, 0.284, 0.175, and 0.198 Å, respectively. Hence, there was no crystallographic evidence of large structural

changes accompanying the enzyme’s binding of PBA relative to when substrate or TS analogue inhibitors are
bound. Furthermore, there were no gross differences in the conformation of the 20s or 50s loops.

Figure 5. Active site architecture of MR with bound PBA. (A) Representative stereoview showing PBA interacting
with active site residues (stick representations) and the Mg2+ ion (sphere) in chain A of the octamer. (B)
Representative stereoview showing PBA (two conformations, each with 50% occupancy) interacting with active
site residues (stick representations) and the Mg2+ ion (sphere) in chain B of the octamer. (C) Stereoview showing
the bound orientations of PBA (solid stick representations) from chain A (gray) and chain B (green), the
intermediate/TS analogue inhibitors BzH (PDB entry 3UXK, blue)(56) and Cfn (PDB entry 3UXL, yellow),(56) and
the substrate analogue (S)-atrolactate (PDB entry 1MDR, pink).(33) The Mg2+ ions (spheres) in the corresponding
MR complexes are shown in the same color as the ligands.
As anticipated, the boron atom of PBA was located between the Nζ and Nε2 atoms of the Brønsted acid–base
catalysts Lys 166 and His 297, respectively (Figure 6). Initial refinements revealed that the electron density could
accommodate PBA with either a trigonal geometry or a tetrahedral geometry, with only slight differences in the
position of the individual atoms. Formation of an N–B bond with the Nζ atom of Lys 166 was not supported by
the electron density. Indeed, the Nζ atom of Lys 166 was directed toward the boronic acid hydroxyl group
located ∼3.2 Å from the Mg2+ ion, suggesting that Lys 166 forms an H-bond with the hydroxyl group, rather than
a dative bond with the boron atom. The average (i.e., over the octamer) Lys 166 Nζ–B distance was ∼2.9 Å,
which is much longer than the Nζ–B distance of 1.67 Å observed for covalent tetrahedral adducts with the εamino group of Lys in other structures(19) and not sufficient to form a dative bond.(88,89) When PBA was
modeled as a single ligand with either a trigonal planar geometry or a tetrahedral geometry, the average His 297
Nε2–B distance was ∼2.5 or ∼2.2 Å, respectively (Table S3), which also did not agree with the expected bond
distances of a dative N–B bond. Typically, Nε2–B distances of ∼1.6 Å have been observed in covalent, tetrahedral
adducts of boronic acid inhibitors with hydrolytic enzymes(83,90,91) and found in calculations.(20) When we
conducted DFT calculations on our system (vide infra), it was clear that the His 297 Nε2–B distances required for
formation of a tetrahedral boronic acid, as suggested from the NMR experiments, were not compatible with the

structure when either sp2- or sp3-hybridized PBA was modeled as a single ligand at the active sites. However, we
noted that the electron density in chains B, D, F, and possibly H could accommodate both sp2- and sp3-hydridized
PBA, as well as two conformations of the imidazole ring of His 297, at 50% occupancy each (Figure 6). Modeling
the PBA ligands and the conformations of His 297 in this manner clearly revealed the presence of a His 297 Nε2–
B dative bond with a length of 1.5 Å in chains B, D, and F. Furthermore, the C–B–Oα–Oβ dihedral angles for the
modeled ligands were in reasonable agreement with those calculated using DFT calculations (Figure S17).

Figure 6. MR with bound PBA at 2.0-Å resolution for all eight subunits (chains A–H) of the homooctamer. The
Mg2+ ion (sphere) and Brønsted acid–base catalysts Lys 166 and His 297 (stick representations) are shown. The
2Fo – Fc map is represented by a gray mesh contoured at 1.0σ. The simulated annealing omit map (Fo – Fc) is
represented by a green mesh centered around PBA, contoured at 2.5σ. The distances are given in angstroms.
In addition to the His 297 Nε2–B interactions, the two boronic acid hydroxyl groups can form multiple H-bonds
and/or electrostatic interactions with the nearby (≤3.6 Å) side chains of Lys 164, Lys 166, His 297, and Glu 317
(Figure 5A,B) that further contribute to the high binding affinity of PBA. Disruption of this H-bonding network
upon substitution of Lys 166 with a Met residue may account for the greater contribution to the binding free
energy observed for Lys 166, relative to His 297, in the ITC studies.
Superposition of (S)-atrolactate, BzH, and Cfn with PBA at the active site (Figure 5C) revealed that PBA assumes a
binding orientation similar to those of the intermediate/TS analogue inhibitors. In chain A, the boron atom was
displaced by 0.8 and 0.6 Å from the corresponding benzylic carbon of BzH and the equivalent nitrogen of Cfn,
respectively, while in chain B, the corresponding displacements were 0.8 and 0.7 Å for the sp2-hybridized PBA

and 1.4 and 1.2 Å for the sp3-hybridized PBA, respectively. Consequently, one of the hydroxyl groups of PBA was
able to maintain H-bonding interactions with Glu 317 and Lys 164, similar to the interactions observed for (S)atrolactate, BzH, and Cfn. Interestingly, this hydroxyl group appeared to occupy the sixth coordination site of the
Mg2+ ion with a Mg2+–O distance of ∼3.2 Å, which resulted in a distorted octahedral coordination geometry
about the divalent cation (Figure S18). The other boronic acid O atom was strongly coordinated to the active site
Mg2+ ion with a Mg2+–O distance of ∼1.9 Å, which is reminiscent of the complex formed between PBA and the
Co3+ ion at the active site of the nitrile hydratase from Pseudonocardia thermophilia.(92) Finally, comparison of
the MR·PBA complex with the complexes of MR with (S)-atrolactate, BzH, and Cfn revealed that, in all cases, the
distance between the Nε2 atom of His 297 and the boron atom of PBA was shorter than the distances between
the Nε2 atom and the corresponding atoms of (S)-atrolactate, BzH, and Cfn, regardless of the hybridization state
of the boron atom (Figure S19).

DFT Calculations

To obtain insights into the effect of varying the His 297 Nε2–B distance on the geometry of the boronic acid
group, we employed LC-ωPBE-XDM/6-31+G* calculations(62) using PBA and 4-methylimidazole. The resulting
correlation (Figure S17) revealed that the average dihedral angle (C–B–Oα–Oβ) of ∼165° observed for ∼sp2hydridized PBA in all chains of the X-ray crystal structure was in reasonable agreement with the average His 297
Nε2–B distance of 2.8 Å, also observed in the structure (Table S3). Similarly, for the ∼sp3-hydridized PBA present
(at 50% occupancy) in chains B, D, and F, the dihedral angles of ∼143° and the N–B distance of 1.5 Å (Table S3)
were also in reasonable agreement with the calculations (Figure S17).

Our observation of a His 297 Nε2–B interaction in the X-ray crystal structure is in accord with the large upfield
change in chemical shift of 27.2 ppm observed in the 11B NMR experiments (Figure 3) and is consistent with
formation of a tetrahedral boronic acid adduct. Typically, the 11B chemical shift of boronic acids changes to a
higher value when the boron atom changes hybridization from sp2 to sp3,(93) and observation of such chemical
shift changes in the 11B NMR spectra of enzyme–boronic acid complexes has often been taken as support for the
formation of sp3-hybridized boronate O–B or N–B adducts.(18,74,79,81−83) In addition to the electron density
of chains B, D, and F supporting occupancy by an sp3- and an sp2-hybridized PBA each at 50%, chains A, C, E, G,
and H supported the presence of an sp2-hydridzed PBA at 100% occupancy. (However, even in those subunits
where only a single conformation was modeled, we cannot rule out the possibility that a range of conformations
is possible within the individual active sites.) While significant steric constraints present at the enzyme active site
may lead to a boron-containing inhibitor assuming an unusual binding mode wherein the boron remains sp2hybridized as a planar ester in some hydrolytic enzymes,(9,94) this does not seem to be the case for the MR-PBA
interaction because the active site certainly tolerates the sp3-hybridized α-carbon of the substrate. Although
development of partial negative charge on the boron atom would mimic the negative charge on the α-carbon of
the altered substrate in the TS, the development of a full negative charge, mimicking the fully deprotonated
intermediate, would likely not favor enhanced binding because it would be accompanied by a (substrate-like)
tetrahedral geometry at the α-carbon. It should also be noted that benzoic acid, with an sp2-hybridized carbon
at the same position as boron in PBA, is an exceptionally weak inhibitor of MR.(70)

To further elaborate on the ability of PBA to form N–B interactions with the side chains of His 297 and Lys 166,
we conducted DFT calculations using an active site model that included PBA and amino acids truncated at the
sp3 or α-carbon atoms with different combinations of protonation states (Table S4). Chain F was used as the
model, refined with a single PBA molecule and a single conformation for the side chain of His 297, as the initial
state. Because of the apparent H-bond between the side chain of Lys 166 and the Oβ atom of PBA (Figure 5A,B),
the ε-amino group of Lys 166 was assumed to be protonated. Upon relaxation, the formation of a tetrahedral
adduct with the Nε2 atom of His 297 was observed (Figure S20). The calculated value of the 11B chemical shift for
the adduct was ∼1 ppm (Table S4), which is in excellent agreement with the observed value of 0.97 ppm.

Interestingly, the DFT calculations revealed that the protonation states yielding the lowest-energy configuration
were Lys 164-NH3+, Lys 166-NH3+, and Glu 317-CO2–. This configuration of protonation states corresponds with
that expected at the intermediate, where the Glu 317-CO22–···HO–B interaction mimics the Glu 317-CO2H···–O–
enolate interaction.(95) Thus, it appears that PBA is being recognized as a TS analogue, consistent with its high
binding affinity. DFT calculations also revealed that for the protonation state Lys 166-NH2/His 297–Im, a His 297
Nε2–B bond formed, and only for the protonation state Lys 166-NH2/His 297–ImH+ did a Lys 166 Nζ–B bond form
(Figure S21). The fact that the X-ray crystal structure furnishes no support for formation of such a Lys 166 Nζ–B
bond supports the notion that the ε-amino group of Lys 166 is protonated in the MR·PBA complex.

Conclusions
Boronic acids have long been known as potent inhibitors of hydrolytic enzymes, forming metastable tetrahedral
adducts with water or the hydroxyl groups of Ser or Thr residues that resemble the intermediate(s) and/or TS(s)
formed during hydrolysis.(5,6,9,22,23) To the best of our knowledge, this is the first report of a boronic acid
acting as a potent inhibitor of an enzyme that catalyzes the abstraction of an α-proton from a carbon acid
substrate. MR binds PBAs with affinities that exceed those observed for the intermediate/TS analogue inhibitors
BzH and Cfn by ∼1–2 orders of magnitude.(43,44) This unprecedented and remarkable binding affinity of PBA
arises from the interaction of the boronic acid function with multiple catalytic residues at the active site
(notably, Lys 164, Lys 166, His 297, and Glu 317), as well as electrostatic interactions with the Mg2+ ion and
formation of a Nε2–B interaction with His 297. The observed interactions at the active site highlight the
versatility of boronic acid–heteroatom interactions in inhibitor design. Moreover, our observations suggest that
boronic acids may serve as inhibitors of other enzymes that share similar active site architectures with MR (i.e.,
Brønsted acid–base catalysts located on either side of a carbon atom where heterolytic C–H bond cleavage
occurs), such as racemases and epimerases, many of which are therapeutic targets.(96)
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